Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists scan brains to find the off-switch for negative thoughts in depression

NCT ID NCT06254144

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study used fMRI brain scans to understand how people with major depression can disengage from negative thinking. Researchers analyzed brain activity patterns during different thinking states in 89 participants. The goal was to identify the neural circuits involved in shifting away from negative thoughts, which could lead to better treatments for depression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help develop brain-based tools to detect and treat negative thinking patterns in depression.
What could go wrong
This is an early-stage observational study with only 89 participants. Results may not apply to everyone with depression, and the findings need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

89 people

The number who actually took part.

Started

Jan 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals with major depressive disorders

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Capable of understanding and complying with protocol requirements. * Participants who are fluent and literate in English and are able to understand and provide written, informed consent and any required privacy authorization prior to the initiation of any study procedures. * Male or female, 18 to 65 years. * Current diagnosis of MDD who are currently depressed defined by the MINI. * Participants who have moderate depressive symptoms (Patient Health Questionnaire: PHQ-9 ≥ 10 or Quick Inventory of Depressive Symptomatology: QIDS-SR ≥ 11). Exclusion Criteria: * Diagnosis of Schizophrenia spectrum or other psychotic disorders. * Bipolar I Disorder. * Active suicidal ideation with a plan and intent or suicidal ideation/attempts in the past 6-12 months. * Current diagnosis of post-traumatic disorder (PTSD) defined by the MINI. * Change in the dose or prescription of medication within the 6 weeks before enrolling in the study that could affect brain functioning. * Moderate to severe substance use disorder within the last 12 months. * A positive test for drugs of abuse, including but not limited to alcohol (breath test), cocaine, marijuana, opiates, amphetamines. * Use of \> 400 mg caffeine or nicotine within the past 2 hours. Medical Conditions * History of unstable liver or renal insufficiency. * Significant and unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, hematologic, rheumatologic, or metabolic disturbance. * Moderate to severe traumatic brain injury or neurocognitive disorders with evidence of neurological deficits. * Co-morbid medical conditions, including cardiovascular (e.g., history of acute coronary events, stroke) and neurological diseases (e.g., Parkinson's, epilepsy). * Co-morbid inflammatory disorders (e.g., rheumatoid arthritis, autoimmune disorders). * Uncontrolled or unstable medical conditions deemed risky by investigators. * Chronic or acute infectious illness (e.g., HIV, SARS-CoV-2). * Current use of hormone-containing medications (excluding contraceptives), immunosuppressive medications, non-steroid anti-inflammatory drugs, or analgesics. MRI Contraindications * Contraindications for MRI (e.g., metal fragments, cardiac pacemaker). Miscellaneous * Unwillingness or inability to complete any of the major aspects of the study protocol. * Non-correctable vision or hearing problems. * Lack of understanding of English. * BMI \> 40 or \< 18.5. * Pregnancy or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depressive disorder, major are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Laureate Institute for Brain Research

    Tulsa, Oklahoma, 74136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.